AbbVie
ABBVWhat is it worth to you? Move six assumptions and see what value per share you get, and where you stand against the price and other users.
At $285.96 (close on November 18) and with the other assumptions at their starting point, AbbVie's sales would need to grow 12.4% a year for ten years; over its last decade, the median was 9.3%. Value it with your own assumptions.
Its accounts, year by year
| Year end | Sales | Growth | Margin |
|---|---|---|---|
| 12/2015 | 22,859 | — | 34.2% |
| 12/2016 | 25,638 | 12.2% | 37.8% |
| 12/2017 | 28,216 | 10.1% | 35.1% |
| 12/2018 | 32,753 | 16.1% | 20.8% |
| 12/2019 | 33,266 | 1.6% | 40.3% |
| 12/2020 | 45,804 | 37.7% | 26.5% |
| 12/2021 | 56,197 | 22.7% | 33.1% |
| 12/2022 | 58,054 | 3.3% | 32.4% |
| 12/2023 | 54,318 | −6.4% | 24.9% |
| 12/2024 | 56,334 | 3.7% | 17.8% |
| 12/2025 | 61,160 | 8.6% | 26.2% |
Sales in millions of dollars. The margin is the operating margin before stock pay, as a percentage of sales. Each row is a fiscal year, by the month it ends. Source: the reports AbbVie files with the SEC, the US securities regulator; the latest is for the fiscal year ended December 31, 2025. See the report.
The model's starting point
- Sales growth, years 1 to 10: 3.7% a year.
- Sales growth after year 10: 2.5% a year.
- Operating margin, before stock pay: 24.9% of sales.
- Working capital needed to grow: −$9.3 per $100 of new sales.
- Capital spending: 1.4% of sales.
- Stock pay to employees: 2.1% of sales.
- Discount rate, the same for every company: 10%.
These are the six assumptions the page starts with; each user moves them as they see fit.
Reference points
They come from its accounts and its share price, compared with the median of the companies on grinboss. They are not a recommendation.
For
- Its share price moves less than the market: a five-year beta of 0.28; the median is 0.94.
- It is one of the big ones: it sells $61.2 billion a year; the median of grinboss companies is $15.1 billion.
- It needs little investment: its capital spending takes 1.4% of its sales; the median is 3.3%.
- Growing brings it cash: it collects from its customers before it pays its suppliers.
Against
- Its margin has fallen over these years, from 35% to 25%.
- Its margin jumps from one year to the next: 8.4 points on average, and up to 19.5 in a single year; the median is 2.8 points.
- It owes a lot: its net debt equals 3.0 years of operating profit plus depreciation and amortization (EBITDA), more than the median (1.5).
- Its growth has slowed: 3.7% a year in the last three fiscal years, against 9.3% over the whole decade.
Next results: January 6, 2027.
Other companies in its sector (Health Care)
Abbott Laboratories (ABT) · Align Technology (ALGN) · Alnylam Pharmaceuticals (ALNY) · Amgen (AMGN) · Baxter International (BAX) · Becton Dickinson (BDX) · Biogen (BIIB) · Bristol Myers Squibb (BMY) · All companies
Loading the model…